Welcome to our dedicated page for Lakeside Holding SEC filings (Ticker: LSH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lakeside Holding Limited (Nasdaq: LSH) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret complex documents. Lakeside identifies itself in these filings as a Nevada-incorporated, U.S.-based integrated cross-border supply chain solution provider and emerging growth company whose common stock trades on The Nasdaq Stock Market LLC.
For investors analyzing LSH, key documents include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe Lakeside’s cross-border freight solutions under the American Bear Logistics brand and its pharmaceutical distribution activities through Hupan Pharmaceutical (Hubei) Co., Ltd. These reports detail revenue composition between third-party and related-party cross-border freight solutions, the contribution from pharmaceutical product distribution, and revenue by customer geographic location.
Current reports on Form 8-K provide timely information about material events, such as the acquisition of Hupan Pharmaceutical, private placements of common stock, convertible debt financings, Nasdaq listing compliance notices, and changes in directors and executive officers. An 8-K also documents that Lakeside’s common stock is listed on Nasdaq under the symbol LSH and that the company is treated as an emerging growth company. Notifications of late filing on Form 12b-25 (NT 10-Q) explain any delays in quarterly report submissions and the expected timing of those filings.
Lakeside’s proxy materials on Schedule 14A outline proposals for stockholder approval, including amendments to the articles of incorporation and bylaws, increases in authorized common stock, authorization of preferred stock, adoption of a treasury reserve strategy, approval of potential future issuances of common stock or convertible securities, and adoption of equity incentive plans. These documents provide insight into the company’s capital structure and governance framework.
On Stock Titan, AI-generated summaries highlight the main points from each filing, helping readers quickly understand topics such as segment disclosures, financing terms, listing status, and board changes. Real-time updates from EDGAR ensure that new LSH filings, including Forms 10-K, 10-Q, 8-K, DEF 14A, and any insider transaction reports on Form 4, are accessible as soon as they are available, with plain-language explanations to support deeper research into Lakeside’s logistics and pharmaceutical distribution businesses.
Lakeside Holding Limited filed a Form 12b-25, notifying a late Quarterly Report on Form 10-Q for the period ended September 30, 2025. The company states it needs additional time to complete certain disclosures and that timely filing would have caused undue hardship and expense, in part due to circumstances referenced in Part IV.
The company expects to file the Form 10-Q on or before the fifth calendar day following the prescribed due date. The notification lists Long Yi as the contact and was signed by Long Yi, Chief Financial Officer (Principal Executive Officer).
Lakeside Holding Limited called a virtual special meeting on November 25, 2025 to seek stockholder approvals for major capital and governance changes. Proposals include increasing authorized common stock to 2,000,000,000 shares and authorizing 1,000,000,000 shares of blank check preferred. The Board also seeks to amend voting thresholds in the Articles to a simple majority and permit name changes without a stockholder vote, and to amend the Bylaws to reduce the quorum to one‑third of outstanding shares.
The agenda requests approval of a Treasury Reserve Strategy to hold Bitcoin and Ethereum, each capped so the Company’s total holdings do not exceed 5% of that cryptocurrency’s market capitalization at acquisition. It also asks approval under Nasdaq Rule 5635(d) for potential non‑public issuances of common stock and/or convertibles at not less than 80% of the Minimum Price, up to 100,000,000 shares and up to $100,000,000 in aggregate gross proceeds. The Company proposes a 2025 Equity Incentive Plan reserving 5,000,000 shares. Shares outstanding were 17,427,559 as of October 16, 2025, the record date.
Lakeside Holding Limited called a special meeting to seek approval for major corporate actions, including raising authorized common stock to 2,000,000,000 shares, creating a class of blank check preferred stock, and a potential company name change. The Board also proposes lowering certain voting thresholds and reducing the meeting quorum to one-third of shares entitled to vote.
The agenda includes a new Treasury Reserve Strategy adopting Bitcoin and Ethereum as primary treasury assets, with each capped at a 5% threshold of that cryptocurrency’s total market capitalization at time of acquisition. The Company also asks to pre‑approve non‑public issuances under Nasdaq Rule 5635(d) of up to 100,000,000 shares (and related convertibles) for up to $100,000,000 in aggregate gross proceeds, and a 2025 Equity Incentive Plan covering 5,000,000 shares. Shares outstanding were 17,427,559 as of October 16, 2025.
Lakeside Holding (LSH) filed its annual report, highlighting a shift to a two-segment model and a challenging year. Total revenue was $17.8 million, down 2.9% year over year, as cross-border freight solutions fell 17.9% amid U.S. trade policy changes and softer demand. The company added a new line in December 2024, generating $2.8 million from pharmaceutical distribution.
Gross profit was $2.9 million (16.2% margin) versus $3.7 million (20.3%) last year, reflecting margin compression in freight (8.8% vs. 20.3%). Pharma posted a 56.1% gross margin, aided by supplier discounts as a new customer. Operating costs rose sharply—selling expenses increased with launch marketing, and G&A climbed 79.1%—driving a net loss of $5.25 million versus a $0.23 million loss a year ago. Interest expense increased 271.5%.
Liquidity at year-end included $5.0 million in cash, a current ratio of 1.06:1, positive working capital of $0.6 million, and $2.8 million in stockholders’ equity. Shares outstanding were 17,427,559 as of October 10, 2025. Management cites tariff uncertainty and de minimis changes as headwinds while scaling the pharma segment.
Lakeside Holding Limited reported changes to its Board of Directors. On September 30, 2025, the Board accepted the resignation of director Ms. Yiye Zhou, effective immediately, and stated that her departure was not due to any disagreement with the company’s operations, policies, or practices.
On the same date, the Board elected Mr. Aik Siang Goh, a technology-focused entrepreneur and executive with over two decades of experience, to serve as a director. Mr. Goh has held senior roles at companies including EdgeMatrix Computing, Chuang House Capital, Amazon Web Services, Fosun Group, Hewlett Packard Enterprise, Dell, and HP. The Board determined that he is an independent director, an “audit committee financial expert,” and a “Non-Employee Director” under applicable Nasdaq and SEC rules.
Mr. Goh will serve on the Audit Committee, the Compensation Committee, and as both a member and chair of the Nominating and Corporate Governance Committee. His compensation will match that of other non-employee directors, and the company reports no related party transactions with him requiring disclosure.
Lakeside Holding Limited has resolved a prior Nasdaq listing issue. The company previously received a notice on July 28, 2025 stating that its common stock had traded below the Nasdaq Capital Market’s minimum bid price of $1.00 per share for 30 consecutive business days, from June 12 to July 28, 2025, putting its listing at risk under Nasdaq Listing Rule 5550(a)(2).
On September 29, 2025, Lakeside received a letter from Nasdaq’s Listing Qualifications staff confirming that it has regained compliance with the minimum bid price requirement, and the matter is now closed. This means the company’s common stock, which trades on the Nasdaq Capital Market under the symbol LSH, currently remains in good standing with this specific listing standard.
Lakeside Holding Limited reported leadership and board changes. The board accepted Lan Su’s resignation as Chairman and Chief Operating Officer, effective immediately, while he continues as general manager of subsidiary Hupan Pharmaceutical (Hubei) Co., Ltd. The board elected Yang Li as a director and appointed him Chief Operating Officer and Chairman of the Board, bringing prior CEO, technology, and investment experience.
The board also elected Xiaoou Li as a new independent director to fill a vacancy. She has more than nine years of financial industry experience and has been designated an audit committee financial expert. She will serve on the audit, compensation, and nominating and corporate governance committees. Following these changes, the board has five members, with a majority independent under Nasdaq rules. The company states that Mr. Su’s resignation is not due to any disagreement and that there are no related-party transactions involving the new directors requiring disclosure.
Lakeside Holding Limited reported that board member Ms. Cynthia Vuong resigned from the Board of Directors effective August 15, 2025. She also stepped down from the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee. The company stated that her resignation was not due to any disagreement with the company on its operations, policies, or practices, indicating this is described as a non-conflict departure.
Lakeside Holding Limited filed an amendment to its current report to correct the disclosed terms of a private placement. The amendment restates Item 1.01 and Item 9.01 to show that the aggregate number of shares issued was 2,000,000 (previously reported as 1,500,000) and that the purchase price per share was $0.75 (previously reported as $1.00). The amendment references an Amended Securities Purchase Agreement filed as Exhibit 10.1 (dated August 5, 2025).
Other than these corrections, the Original report filed on July 22, 2025 remains unchanged. The amendment is signed by CFO Long Yi on August 11, 2025. The filing identifies the company as a Nasdaq-listed registrant under the ticker LSH and indicates it is an emerging growth company.
Lakeside Holding Limited entered into a Securities Purchase Agreement to issue an aggregate of 1,807,229 shares of common stock at $0.83 per share, producing gross proceeds of approximately $1,500,000.07. The agreement contains customary representations, warranties and covenants, and the company intends to use the net proceeds for general corporate purposes.
The offering was completed as a private placement relying on exemptions under Section 4(a)(2) and/or Regulation S of the Securities Act; the shares are unregistered and may not be offered or sold in the United States absent registration or an applicable exemption. The form of the Securities Purchase Agreement is filed as Exhibit 10.1.